Genome Location Dictates the Transcriptional Response to PolC Inhibition in Clostridium difficile.

ABSTRACT: Clostridium difficile is a potentially lethal gut pathogen that causes nosocomial and community-acquired infections. Limited treatment options and reports of reduced susceptibility to current treatment emphasize the necessity for novel antimicrobials. The DNA polymerase of Gram-positive organisms is an attractive target for the development of antimicrobials. ACX-362E [N²-(3,4-dichlorobenzyl)-7-(2-[1-morpholinyl]ethyl)guanine; MorE-DCBG] is a DNA polymerase inhibitor in preclinical development as a novel therapeutic against C. difficile infection. This synthetic purine shows preferential activity against C. difficile PolC over those of other organisms in vitro and is effective in an animal model of C. difficile infection. In this study, w

SUBMITTER: van Eijk E 

PROVIDER: S-EPMC6355584 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature